Latest LXEO news

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

PRNewsWire · Wed, 23 Sep 2026 08:00:00 -0400

NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia.

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

GlobeNewsWire · Wed, 23 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET.

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

Seeking Alpha · Tue, 22 Sep 2026 13:49:48 -0400

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga · Tue, 22 Sep 2026 08:01:07 -0400

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.2% on Tuesday.

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

GlobeNewsWire · Tue, 22 Sep 2026 07:00:00 -0400

Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease SUNRISE-FA 2 pivotal study continues enrollment and remains the company's top priority development program; topline data on track for 2H 2027 Disciplined capital allocation supports these strategic initiatives while maintaining cash runway into 2028 Company to host webcast today at 8:00 AM ET NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced a series of strategic transactions to expand its presence in Friedreich ataxia (FA), including the signing of a definitive agreement to acquire Mantle Therapeutics Inc. and three new research collaborations supporting cerebellar-targeted development opportunities for frataxin gene therapy.

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

GlobeNewsWire · Wed, 02 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced that members of management will participate in the following investor conferences in September: Cantor Global Healthcare Conference 2026.

Lexeo Therapeutics Reports Second Quarter 2026 Financial Results and Operational Highlights

GlobeNewsWire · Wed, 12 Aug 2026 07:00:00 -0400

Finalized SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 in support of accelerated approval pathway; topline data expected in second half of 2027 Initiated SUNRISE-FA 2 with first patient enrolled into pivotal study in June; site activation efforts ongoing CLARITY-FA enrollment continues to advance, supporting identification of eligible participants for SUNRISE-FA 2 FDA granted RMAT designation for LX2020 based on recent interim clinical data in PKP2-ACM Cash, cash equivalents and investments of $234.2 million expected to provide operational runway into 2028 NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today provided business updates across its portfolio and reported financial results for the second quarter 2026. “We closed the second quarter with significant momentum, highlighted by the initiation of SUNRISE-FA 2, the pivotal study for LX2006 in Friedreich ataxia cardiomyopathy,” said R.

Market information is provided for research and visualization and is not investment advice.